Product Description
Concizumab is a monoclonal, humanized IgG4 antibody specific for the Kunitz-2 domain of Tissue Factor Pathway Inhibitor (TFPI). Preclinical studies in vitro or on animal models and in vivo have demonstrated the ability of concizumab to restore thrombin generation, promoting the establishment of a procoagulant action; all these results were subsequently confirmed in the studies of EXPLORER program. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020573/#:~:text=Concizumab%2C%20an%20anti%2Dtissue%20factor,Hemophilia.)
Mechanisms of Action: SPINT2 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Algeria, Australia, Austria, Bosnia, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Lithuania, Malaysia, Mexico, North Macedonia, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Thailand, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Hemophilia A|Hemophilia B|Injuries/wounds Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NN7415-4616 | P3 |
Unknown Status |
Injuries/wounds Unspecified |
2029-11-02 |
|
| NN7415-4307 | P3 |
Unknown Status |
Injuries/wounds Unspecified |
2026-06-09 |
|
| EXPLORER 10 | P3 |
Active, not recruiting |
Injuries/wounds Unspecified |
2026-04-05 |
|
| NN7415-4311 | P3 |
Unknown Status |
Injuries/wounds Unspecified |
2025-12-31 |